TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01753102
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one tablet will be inserted daily for 14 days
Study: NCT00410228
Drug: AHT956
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00240227
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01692171
Drug: Heparin, Low-Molecular-Weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
Study: NCT02144584
Drug: Placebo (for memantine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be capsuled to look identical to active drug (memantine)
Study: NCT04190173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/2-1 tablet once daily enteral feeding for 5 consecutive days
Study: NCT03833388
Drug: TOP1630 0.1% Ophthalmic Solution TID OU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ocular drug administration
Study: NCT03833388
Drug: Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ocular drug administration
Study: NCT02500381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP-4045 or SRP-4053 placebo-matching solution for IV infusion
Study: NCT03530800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 10 weeks
Study: NCT02963935
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
Study: NCT02273531
Drug: Asasantin ER, new formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02273531
Drug: Asasantin ER, present commercial formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02337738
Drug: TVP-1012 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVP-1012 1mg Tablets
Study: NCT02337738
Drug: TVP-1012 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVP-1012 0.5mg Tablets
Study: NCT02337738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablets
Study: NCT00130676
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily for 7 days
Study: NCT02649231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline
Study: NCT00437281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03208959
Drug: HTI-1090
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDO/TDO inhibitor
Study: NCT01875445
Drug: Inositol
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
Study: NCT01875445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
Study: NCT02103647
Drug: Immediate release capsule(lyrica 150mg * 2/day)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release capsule
Study: NCT02103647
Drug: sustained release tablet
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained release tablet
Study: NCT00189397
Drug: azathioprine and corticosteroids for Parthenium dermatitis
Normalized name: parthenium hysterophorus extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02544061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single subcutaneous dose
Study: NCT04405206
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cape 1000mg/m2
Study: NCT02269046
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/d,p.o,12 weeks.
Study: NCT00557973
Drug: XP19986 SR1, 10 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
Study: NCT00557973
Drug: XP19986 SR1, 20 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
Study: NCT00557973
Drug: XP19986 SR1, 30 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
Study: NCT00557973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.
Study: NCT02578771
Drug: ZuraPrep with 70% IPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically
Study: NCT02578771
Drug: ZuraPrep without 70% IPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically. 0% IPA
Study: NCT02578771
Drug: ChloraPrep CHG/IPA Teal Tint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically
Study: NCT02047227
Drug: Pergoveris®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
Study: NCT02047227
Drug: GONAL-f®
Approvals — FDA: no, EMA: no, PMDA: no
Description: GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
Study: NCT02047227
Drug: Recombinant human chorionic gonadotrophin (r-hCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
Study: NCT01977937
Drug: Simple Syrup
Normalized name: Simple syrup
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01428362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04753476
Drug: Standard treatment of Covid-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given Standard treatment of Covid-19 which accordance with National protocol
Study: NCT03004443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution will be administered intravenously over a 2 to 2.5 hour period.
Study: NCT00828854
Drug: Aromatase Inhibitor (AI) Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI therapy at labeled dose and schedule as prescribed in clinical practice. AI therapies include: Arimidex® (anastrozole) 1 mg/day by mouth (PO), Fermara® (letrozole) 2.5 mg/day PO , Aromasin® (exemestane) 25 mg/day PO.
Study: NCT00116428
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
Study: NCT03550950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as IV infusion or SC injection.
Study: NCT01525706
Drug: Ethanol and Paclitaxel Injection
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL \[3mg/ml diluted in normal saline from original concentration of 6mg/mL\] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
Study: NCT04253912
Drug: VBP-245
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Povidone-Iodine Gel
Study: NCT02031211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
Study: NCT04627337
Drug: Saccharomyces Boulardii 250 MG
Normalized name: Saccharomyces boulardii 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yeast in capsules
Study: NCT00487682
Drug: ASP2151
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03316339
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid anesthesia
Study: NCT00236782
Drug: norelgestromin + ethinyl estradiol; mercilon
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03080194
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject in control group will be applied with oral antipsychotics or other conventional medication.
Study: NCT00111189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 4 wk up to 24 mo
Study: NCT01273103
Drug: 200mg [14C]- GSK2248761
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral suspension dose of \[14C\]- GSK2248761 200 mg
Study: NCT03539003
Drug: propofol and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: anesthesia was induced with an effect-site concentration of 3-4 μg/ml propofol and 2-3 ng/ml remifentanil using target-controlled infusion (TCI). After intubation, The effect site TCI of propofol (2-3 μg/ml) and remifentanil (1.0-2.0 ng/ml) was adjusted to maintain the desired hypnosis (40-60 of the BIS value) during surgery.
Study: NCT02395783
Drug: Melatonin 10 µg
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
Study: NCT00600626
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01683253
Drug: Levodopa/Carbidopa(200mg/50mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01683253
Drug: Dopaminergic Agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated for at least 6 months after diagnosis of Parkinson's Disease.
Study: NCT02395783
Drug: Melatonin 20 µg
Normalized name: melatonin 20 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
Study: NCT03029273
Drug: Cyclophosphamide and Fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with cyclophosphamide (250-500mg/m2/day) plus fludarabine (25mg/m2/day) for 3 days.
Study: NCT01928914
Drug: Placebo for moxifloxaxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
Study: NCT00542516
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
Study: NCT01577537
Drug: 1% SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel, daily for 7 days
Study: NCT01577537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel, daily for 7 days
Study: NCT01162928
Drug: Nutriflex Omega special + Oxepa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-chamber-bag combined with enteral nutrition
Study: NCT01162928
Drug: Nutriflex Lipid special + Pulmocare
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-chamber-bag combined with enteral nutrition
Study: NCT01501383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01674283
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00052273
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02315326
Drug: HD- Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm C1: HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a total of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments.The starting dose of ibrutinib is 560 mg/day (4x140mg capsules)
Study: NCT02431845
Drug: SSRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents
Study: NCT00514293
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00754988
Drug: Placebo (matching sitagliptin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral administration of placebo (matching sitagliptin).
Study: NCT00418782
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00418782
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00754988
Drug: Placebo (matching taspoglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
Study: NCT04473846
Drug: PK general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be anesthetized using Fentanyl (2 mcg/kg) and Propofol (1-2 mg/kg).
Study: NCT04473846
Drug: PFK combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient received an initial dose of 0.05 ml/kg from the solution, then after waiting for 60 seconds, another 0.05 ml/kg were given. Maintenance was given as boluses of 0.025 ml/kg every three to five minutes.
Study: NCT04143087
Drug: withdrawal TKIs or halve TKIs
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop TKIs or treated by half TKIs
Study: NCT00223171
Drug: Androgen blockade + radiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen blockade + radiation therapy
Study: NCT04416984
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for lymphodepletion
Study: NCT00675259
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
Study: NCT01652196
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
Study: NCT01652196
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
Study: NCT03396523
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of placebo (oral)
Study: NCT05737329
Drug: Transdermal estradiol gel 0.1% 1.5mg/ day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol gel 0.1% 1.5mg/ daily + Micronized Progesterone 200mg
Study: NCT00064181
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00064181
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00064181
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00064181
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00064181
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01739361
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01739361
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01044251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tab po bid for 10 days
Study: NCT01462643
Drug: LAS41004
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, topical ointment, 100 microgram per day
Study: NCT00472446
Drug: placebo bilateral superficial cervical block
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.~Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.
Study: NCT04183790
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) tablet for oral administration
Study: NCT03664180
Drug: Unfractionated heparin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
Study: NCT00658320
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
Study: NCT01830920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A normal saline solution identical in appearance to the active drug solution
Study: NCT01532882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, PO, 1 per day during 28 days
Study: NCT02585258
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule containing a tablet of 5 mg prednisolone/ day
Study: NCT01169090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01987284
Drug: SER100
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01987284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02959983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching eluxadoline oral tablets BID with food.
Study: NCT00789802
Drug: transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
Study: NCT00789802
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
Study: NCT00789802
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
Study: NCT02277223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is \>35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin.
Study: NCT01689636
Drug: Tc 99m EC20
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00774332
Drug: CODOX-M
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine
Study: NCT01313728
Drug: Dapsone plus Tretinoin Gel
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
Study: NCT01313728
Drug: Tretinoin Gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
Study: NCT00621959
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg (matching oral tablet)for 14 days
Study: NCT00041288
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes